Articles tagged with Neurodegenerative Diseases
A cross-sectional study of 170 former football players found a strong association between repeated head impacts and increased perivascular space volume, as well as worse cognitive test performance. The findings suggest that PVS volume may contribute to the link between RHI exposure and neurodegeneration.
Researchers have identified two proteins, PARP1 and histone H1.2, that interact with an ALS-causing mutant FUS protein, leading to pathological changes. Inhibiting these proteins may be a possible therapeutic target for familial ALS cases caused by mutations in the FUS gene.
Scientists at IOCB Prague have developed a new compound that suppresses appetite and protects the brain against Alzheimer's disease. The modified molecule, derived from the neuropeptide CART, is effective in reducing pathology associated with Alzheimer's.
Researchers discovered that Huntington's disease protein aggregates cause breaks in the nuclear envelope, leading to DNA damage and misregulation of neuronal genes. The study suggests a common mechanism for neurodegenerative diseases involving nuclear aggregate-induced ruptures.
Researchers explore the phenomenon of liquid-liquid phase separation (LLPS) in relation to cancer and neurodegenerative diseases. LLPS is characterized by the spontaneous formation of segregated liquid-phase regions within cells, which can lead to the formation of aggregates and dysregulation of signaling pathways.
The International Space Station National Laboratory is collaborating with NASA to fund up to $4 million in research addressing significant diseases like cancer, cardiovascular disease, and neurodegenerative disease. The joint solicitation aims to leverage microgravity to improve existing or develop new technologies for health problems ...
A University of Michigan-led study found that higher levels of metals in blood and urine are associated with a greater risk for ALS and shorter survival. Occupational exposure to metals was also linked to increased metal levels, emphasizing the need for accounting for environmental factors when evaluating overall exposure risk.
Researchers developed a new visual diagnostic technique called Cap-QuIC that can distinguish infected samples with the naked eye, enabling faster and more accurate disease detection. The method builds upon previous groundbreaking diagnostic techniques and leverages simple action to detect misfolded alpha-synuclein proteins.
Researchers found that dopamine treatment increased neprilysin levels and reduced beta-amyloid plaques in mouse brains, improving memory function. Long-term L-DOPA treatment also showed improved cognitive performance in mice.
Researchers developed a method to study aged neurons in the lab without a brain biopsy, revealing aspects of cells' genomes linked to late-onset Alzheimer's development. The technique suggests new treatment strategies targeting retrotransposable elements and early intervention to slow disease progression.
University of Utah researchers have developed a targeted therapy approach using alpha particles to break down harmful amyloid beta plaques, potentially slowing the devastating neurodegenerative disease. The treatment, called Targeted Alpha Therapy, delivers particles directly to the plaques while minimizing damage to healthy tissues.
Researchers discovered elevated levels of neurofilament light chain protein in Parkinson's disease and dementia with Lewy bodies, suggesting potential early detection methods. The study found different protein patterns between the prodromal stage and established diseases.
A new study suggests that public health interventions, such as reformulating food products and introducing low emission zones, could yield significant cost savings and QALY gains in England. The interventions studied could save up to £4bn by reducing dementia rates and helping people live longer and healthier.
Researchers used advanced imaging techniques to create detailed maps of mouse brains, identifying areas vulnerable to blood vessel degeneration. These changes can lead to cognitive decline and neurodegenerative disorders like Alzheimer's disease.
The PD GENEration study has found that 13% of participants have a genetic form of Parkinson's disease, significantly higher than previous estimates. The study, which reached its goal of 15,000 participants ahead of schedule, provides insights into the genetics of the disease and its potential for precision medicine.
Researchers found anomalies in embryonic development of individuals with spinal muscular atrophy (SMA), which could lead to new treatment options. These abnormalities were recreated in laboratory-grown tissue cultures called organoids, revealing key insights into the disease's progression.
Researchers from Tokyo Medical and Dental University demonstrate a proof of concept for antisense nucleic acid therapy to prevent the spread of α-synuclein pathologies in synucleinopathies. The treatment, involving antisense oligonucleotides, effectively reduces Lewy pathology-like neuronal inclusion by over 90%.
A new study reveals specific brain regions and cell types that are vulnerable to Alzheimer's disease, while others show resilience. Gene expression analysis and lab experiments highlight the role of Reelin in neuronal vulnerability and choline/antioxidants in sustaining cognition.
A study by Durham University found that retired rugby players with multiple concussions have higher levels of proteins linked to neurodegenerative diseases, such as Alzheimer's and motor neurone disease. The research suggests monitoring athletes' blood for these biomarkers may help diagnose early disease and prevent future development.
Researchers investigated the relationship between protein aggregation and liquid-liquid phase separation, finding that droplet formation may actually protect against aggregation. The study, led by Paul Scherrer Institute, used over 500 conditions to test the behavior of alpha-synuclein proteins.
A study by Sant Pau Research Institute identified a new mutation in the ARPP21 gene linked to amyotrophic lateral sclerosis (ALS) in 10 patients from 7 unrelated families. The finding suggests that ARPP21 is a novel ALS-causing gene with potential for personalized therapies and diagnosis.
Researchers discovered a new genetic cause of inherited Parkinson's disease, the CARS E795V mutation, which affects protein function and leads to neurological symptoms. The study found that this rare mutation is responsible for the condition in nine individuals from four families.
A new immune cell therapy has been shown to delay ALS onset and extend survival in mice, as well as reduce inflammation in an individual with the disease. In a phase I clinical trial, the therapy is now set to be tested on humans.
A new study published in Nature Communications found that smoking is a key lifestyle factor contributing to cognitive decline among older adults. Non-smokers who engaged in healthy behaviors such as regular exercise, moderate alcohol consumption, and social activity experienced significantly slower cognitive decline compared to smokers.
A Harvard study found that people who followed a healthy diet from their 40s onward were 43-84% more likely to be well-functioning physically and mentally at age 70 compared with those who did not. Adhering to diets rich in fruits, vegetables, whole grains, and healthy fats was associated with greater odds of healthy aging.
A study found that targeting heparan sulfate-modified proteins improves cell repair, rescues neuron loss and reverses cellular changes associated with neurodegenerative diseases. Disrupting these proteins promotes autophagy-dependent cell repair and reverses early cellular problems in models of Alzheimer's.
Biomolecular condensates exhibit unique material properties tied to protein sequences, including viscoelastic behavior and aging processes. The study quantifies interaction timescales, explaining how proteins within condensates arrange into fibrils over time.
Researchers develop a method that fuses AlphaFold's strengths with computer simulations based on physics laws to predict protein structures, enabling faster drug development. The approach filters down initial hypotheses to a more manageable set of structures, increasing the effectiveness of pharmaceuticals.
A groundbreaking clinical trial has shown that gene therapy can halt the progression of spastic paraplegia type 50 (SPG50) in a young boy. The treatment, delivered via spinal fluid, eliminated serious side effects and showed potential signs of improvement.
A team of researchers will study the effects of TBI on neurodegeneration to gain insight into ADRD development. They aim to uncover the underlying biological mechanisms and identify factors that increase the risk of ADRD.
Researchers from PSI and ETH Zurich studied connexin-36 gap junction channels and found that antimalarial drug mefloquine binds to the channels, potentially explaining its severe side effects. The study provides new insights into how drugs interact with connexins and may lead to the development of therapies for neurological diseases.
Researchers at Colorado State University used human stem cells to study synaptic connections in the brain, focusing on GABAergic synapses. They found that Gephyrin promotes autonomous assembly of these synapses, which can develop independently of neuronal communication. This understanding could lead to new treatments for neurological d...
A landmark clinical trial collaboration has reported significant improvements in neurobehavioral and functional outcomes for children with moderate to advanced stages of Sanfilippo syndrome. The study found anakinra, a recombinant interleukin-1 receptor antagonist, to be safe and effective in reducing disease symptoms.
A study by TUM researchers discovered four subtypes of Amyotrophic Lateral Sclerosis (ALS) with different molecular processes, including sex differences. The findings suggest repurposing an approved cancer drug targeting the MAPK pathway as a promising therapeutic approach for ALS.
Researchers found that men taking terazosin-type medications had about a 40% lower risk of developing dementia with Lewy bodies compared to those taking tamsulosin or 5-alpha reductase inhibitors. The study suggests that these drugs may have broad potential for treating neurodegenerative conditions.
Dorothee Dormann and Edward Lemke propose a new concept to measure the individual risk of getting age-related diseases by analyzing protein clumps in cells. This 'protein aggregation clock' could help diagnose age-related diseases at early stages or identify people at higher risk.
Researchers developed an AI-based screening tool that differentiates Alzheimer's disease and Lewy body disease by analyzing eye movement patterns. The tool provides a reliable method for identifying and distinguishing between the two dementia forms, which can aid in mitigating their impact on daily activities.
A new AI-driven tool can accurately diagnose Lewy body dementia by analyzing changes in vocal emotional expressions. The study found that individuals with Lewy body dementia exhibited more negative and calmer emotional expressions compared to those with Alzheimer's disease and healthy controls.
Researchers at the University of Rochester Medical Center found that ketones can rescue impaired neuronal function in the hippocampal network. This study suggests a potential therapeutic approach for preventing or delaying neurodegenerative diseases like Alzheimer's.
Researchers have developed a new mathematical tool to study cell protein degradation rates, which helps understand cell growth, death, and aging. The study found that not all proteins degrade at the same pace, with some breaking down in minutes, hours, or days.
Researchers developed a new system to prevent dementia, which was tested on 30 volunteers with mild cognitive impairment. The system showed a significant reduction in cognitive impairments after six weeks of training.
Researchers have discovered a small molecule compound called ESI1 that can regenerate vital myelin coatings, potentially treating multiple sclerosis and age-related cognitive deficits. The treatment promotes healing by clearing a roadblock in the repair process, allowing oligodendrocytes to produce myelin sheaths.
Scientists identify ZIP7 as a key player in reducing ER stress, which is responsible for misfolded protein accumulation. Overexpressing ZIP7 restores cell mobility, suggesting its potential as a therapy target for degenerative diseases.
Researchers identify TRMT10C enzyme causing methylation of ND5 mRNA, leading to mitochondrial dysfunction and reduced energy supply to the brain. Impairment of complex I in the respiratory chain contributes to Alzheimer's disease pathology.
Researchers have developed a magnetic coil array called MagPatch that can stimulate individual neurons with precision. The device uses soft magnetic materials to boost the magnetic field, reducing the need for high current levels.
Researchers used machine learning to analyze over 1.09 million potential metabolite-receptor pairs and predict the likelihood that each interaction contributed to Alzheimer's disease. The study found a protective metabolite called agmatine interacting with a receptor called CA3R in brain cells, reducing CA3R levels and lowering phospho...
Depletion of axonal mitochondria disrupts autophagy, leading to abnormal protein build-up in neurons. Restoring mitochondrial levels restores autophagy and recovers impaired neuron function.
Researchers at Gladstone Institutes have identified a blood coagulation protein, fibrin, as the culprit behind toxic inflammation and neuron loss after a major head injury. This finding can inform new treatment strategies for traumatic brain injuries, which often lead to dementia, depression, and difficulty concentrating.
Emerging from a need to understand organelle interactions, researchers have developed OrthoID, a novel strategy that refines protein identification at organelle contact sites. This method uses mutually orthogonal binding pairs to label and isolate proteins involved in cellular communication.
Researchers found a significant association between storing chemicals in attached garages and increased ALS risk. The study suggests that volatile chemicals released into the living space may contribute to this link.
Air pollution exposures are linked to increased risk of neurodegenerative diseases such as Alzheimer's and Parkinson's. The new PM2.5 standard may not be sufficient to mitigate these risks, especially for vulnerable populations.
Researchers discovered that mature oligodendrocytes, critical for brain function, can survive for up to 45 days after a fatal trauma, defying the classical programmed cell-death pathway. This finding opens new avenues for understanding and potentially preventing damage caused by aging and neurodegenerative diseases.
A study using a xenotransplantation model has revealed that human microglia respond to amyloid-β plaques with a complex immune response, influencing the disease course. The research highlights the importance of considering genetic factors in microglia-targeted therapies for Alzheimer's disease.
McGill researchers have made a groundbreaking discovery about Spinocerebellar ataxia type 6, a rare and devastating neurodegenerative disease. Damaged mitochondria in the cerebellum are found to contribute to disease progression.
Researchers have identified PDE4B as a potential target for treating Alzheimer's disease, where reducing its activity shows promise in improving memory and glucose metabolism. The study suggests that this approach may also protect against other forms of dementia, such as Huntington's disease.
Rats consuming reheated sesame or sunflower oil showed increased oxidative stress and inflammation in the liver, leading to significant damage in the colon and changes in endotoxins. The study suggests that long-term deep-fried oil consumption may contribute to neurodegeneration and highlight the need for further research on this topic.
A recent study published in Cell reveals significant similarities between amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD), two distinct neurological disorders. The research found shared gene expression patterns across various brain regions, suggesting potential therapeutic targets for both conditions.
Researchers at University of Pittsburgh are developing a platform to genetically modify glia cells using bioengineering modified RNAs. The goal is to increase or decrease disease-relevant genes in astrocytes or microglia to potentially treat Alzheimer's disease and other neurodegenerative disorders.
A clinical trial at NIH demonstrated that experimental gene therapy slowed loss of motor function in patients with giant axonal neuropathy, a fatal childhood disease. The treatment also showed signs of regeneration in sensory nerves, offering new hope for those affected.
The American Society for Biochemistry and Molecular Biology's annual meeting features exciting research findings on antibacterial compounds, whooping cough infection, nicotine addiction, and more. Complementary on-site press passes will be issued to a limited number of attendees.